Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
Add filters








Type of study
Year range
1.
China Pharmacist ; (12): 255-263, 2024.
Article in Chinese | WPRIM | ID: wpr-1025942

ABSTRACT

Objective To mine temozolomide-related adverse drug event(ADE)signals in the real world and to provide a reference for the safe clinical use of temozolomide.Methods The U.S.Food and Drug Administration Adverse Event Reporting System(FAERS)was used to collect the ADE reporting data of temozolomide in the FAERS database from January 1,2004 to December 31,2022.The signal mining was performed using the report ratio method and Bayesian confidence interval progressive neural network method to analyze the occurrence of ADE.Results In the database,there were 24 725 ADE reports with temozolomide as the primary suspected drug,and a total of 300 ADE signals were identified,involving 23 system organ categories,and the top 5 were blood and lymphatic system diseases,systemic diseases and various reactions of administration sites,various examinations,various neurological diseases,various injuries,poisoning and procedural complications etc.the most frequently reported ADE signals included thrombocytopenia,low platelet count,neutral granulocytopenia,pancytopenia,convulsive attacks,and febrile neutropenia.42 new suspected adverse reactions were discovered,which were not recorded in the instructions,such as pseudomonas skin infection,herpetic meningoencephalitis,hypoglossal nerve paralysis,porokeratosis,etc.Conclusion The common adverse reactions of temozolomide in the real world are generally consistent with the instructions,but some new suspicious adverse reactions have been discovered.During clinical drug use,special attention should be paid to these new adverse reactions,and it is recommended to monitor patients'adverse reactions and take appropriate measures in a timely manner.

2.
China Pharmacy ; (12): 739-743, 2024.
Article in Chinese | WPRIM | ID: wpr-1013112

ABSTRACT

OBJECTIVE To provide reference for safe drug use in clinic by mining the adverse drug events (ADE) of 3 kinds of anti-influenza A virus drugs (oseltamivir, zanamivir, baloxavir marboxil). METHODS The ADE data of oseltamivir, zanamivir and baloxavir marboxil were collected from the FDA adverse event reporting system (FAERS) between the first quarter in 2004 and the third quarter in 2022, and mined by using reporting odds ratio (ROR) method. The designated medical events (DME) were estimated. The system organ class (SOC) in the Medical Dictionary for Regulatory Activities (MedDRA, version 25.0) was used for the classification and statistics of drug ADE terminology. RESULTS A total of 12 636, 1 749 and 1 283 ADE reports were retrieved for oseltamivir, zanamivir and baloxavir marboxil, involving 26, 16 and 17 SOCs, respectively. Oseltamivir was strongly associated with sleep terror, abnormal behavior, hallucination and delirium. Zanamivir was implicated in abnormal behavior, delirium, incoherence, and altered state of consciousness with prominent signal intensity. Baloxavir marboxil was strongly associated with ischemic colitis, hemorrhagic cystitis, erythema multiforme and melaena. Erythema multiform was detected in the DME of three drugs with strong signals. CONCLUSIONS When clinically administering the three drugs, it is crucial to pay close attention to both common adverse reactions and those ADEs that are not explicitly mentioned in the drug instructions. For oseltamivir, clinicians should exercise caution due to the potential risk of acute kidney injury and fulminant hepatitis, necessitating regular monitoring of the patient’s liver and kidney function. When prescribing zanamivir, caution should be exercised due to ADEs related to the respiratory system, including acute respiratory distress syndrome and respiratory failure, necessitating close monitoring of the patient’s respiratory status. Similarly, for baloxavir marboxil, clinicians should be vigilant for potential ADEs such as erythema multiforme and rhabdomyolysis.

3.
China Pharmacy ; (12): 210-213, 2024.
Article in Chinese | WPRIM | ID: wpr-1006180

ABSTRACT

OBJECTIVE To mine the adverse drug event (ADE) signals of selinexor, and to provide reference for its clinical safety medication. METHODS ADE data for selinexor reported from July 3rd, 2019 to March 31st, 2023 were collected from the FDA adverse event reporting system (FAERS). Data mining was performed by using the reporting odds ratio (ROR) and proportional reporting ratio (PRR) methods, and categorization statistics were performed by using the system organ class (SOC) and preferred term (PT) from drug ADE terminology set in the MedDRA (version 26.0). RESULTS A total of 3 084 ADE reports were obtained for selinexor, with a total of 134 ADE-positive signals. Among the reported genders, there were 127 males and 124 females, with a predominant age of ≥65 years old (4.12%); the United States had the highest number of reports (96.53%), with consumers being the main reporters (77.27%); severe ADR was mainly characterized by hospitalization/prolonged hospitalization (26.26%), followed by death (17.15%). The top 3 ADE in the list of frequency were nausea (1 162 times), fatigue (790 times) and anorexia (610 times), all of which were mentioned in the selinexor’s instructions. The top 3 signals in the list of strength were device-associated bacteremia (ROR=115.07, PRR=114.94), blepharospasm dysfunction (ROR=106.70, PRR=106.54), and salmonella sepsis (ROR=99.90, PRR=99.81), all of which were not mentioned in the selinexor’s instructions. CONCLUSIONS In addition to the ADE of nausea mentioned in the instruction manual, attention should also paid to device-associated bacteremia, blepharospasm dysfunction, salmonella sepsis, and other ADE not mentioned in the instruction manual when using selinexor in clinical practice; weekly rechecking of the patient’s blood routine should be done to monitor the patient’s blood indexes, symptoms of infection, and so on, to ensure that the safety of 1661962346@qq.com drug use.

4.
China Pharmacy ; (12): 339-342, 2024.
Article in Chinese | WPRIM | ID: wpr-1006620

ABSTRACT

OBJECTIVE To explore and analyze the adverse drug event (ADE) signals of darolutamide and provide a reference for its clinical safe use. METHODS ADEs related to darotamide were collected based on the US FDA adverse event reporting system (FAERS) database from the third quarter of 2019 to the third quarter of 2022. Data mining and analysis were conducted by the report odds ratio (ROR) and proportional reporting ratio (PRR) methods. RESULTS A total of 565 ADE reports related to darolutamide were extracted, 356 ADE reports about darolutamide as the primary suspected drug were included, 38 ADE signals with darolutamide as the primary suspected drug were excavated, involving 15 system organ class (SOC), mainly concentrated in patients over 65 years old. The SOC of darotamide ADE signal mainly focused on various examinations, systemic diseases and various reactions at the administration site, benign/malignant tumors or those with unknown nature (including cystic and polypoid), kidney and urinary system diseases. A total of 13 ADE signals not mentioned in the instructions included increased prostate-specific antigen, dysphagia, cognitive impairment, erectile dysfunction, rhabdomyolysis, gynecomastia and decreased platelet count, etc. CONCLUSIONS When using darolutamide, in addition to ADE in the drug instruction, we should pay close attention to potential ADE, such as increased prostate-specific antigen, rhabdomyolysis, gynecomastia and decreased platelet count, so as to avoid drug withdrawal or organ damage caused by ADE.

5.
China Pharmacy ; (12): 348-352, 2024.
Article in Chinese | WPRIM | ID: wpr-1006622

ABSTRACT

OBJECTIVE To provide reference for clinically safe drug use by mining oxaliplatin-related adverse drug events (ADE) of the nervous system. METHODS Oxaliplatin-related neurologic ADE data reported by the FDA adverse event reporting system (FAERS) between January 1st, 2004 and December 31st, 2022 were collected. The reporting odds ratio and proportional reporting ratio were used for data mining. The data were classified statistically by using systematic organ classification, high-level group term (HLGT) and preferred term (PT) in the MedDRA (version 26.0). RESULTS A total of 7 266 cases of oxaliplatin- related ADE, which were classified as various neurological, were retrieved, and 100 PT were identified. Of these, fifty-seven PT were unspecified adverse reaction signals in the manual. Among these reports, males (46.85%) were more than females (42.98%), the age of patients was 45-<75 years (65.22%), the number of reports was highest in Italy (16.32%), and the severe type was hospitalization or prolonged hospitalization (38.16%). The top 5 PT reports in the list of case number were peripheral neuropathy, paresthesia, neurotoxicity, loss of consciousness and dysarthria. The top 5 PT reports in the list of signal intensities were cold- induced paresthesia, neuromuscular rigidity, acute polyneuropathy, neuronal neuropathy, axonal and demyelinating polyneuropathy. A total of 13 HLGT were involved, with neurological diseases (not classified separately) having the highest number of signals (29). CONCLUSIONS When using oxaliplatin in clinical practice, it is not only necessary to monitor the high incidence of acute and chronic peripheral neuropathy, but also to pay attention to the patient’s consciousness state and neurological symptoms. We should pay attention to the rare types of adverse reactions, such as guillain-barre syndrome, Lhermitte sign, posterior reversible encephalopathy syndrome, and hyperammoniacal encephalopathy, so as to ensure the safety of medication.

6.
Article in Chinese | WPRIM | ID: wpr-1023180

ABSTRACT

Objective Based on U.S.Food and Drug Administration Adverse Event Reporting System(FAERS)database,the signal mining of tizanidine adverse drug events(ADEs)was conducted to explore the occurrence characteristics of ADE,hoping to provide references for the safe clinical application of tizanidine.Methods The reporting odds ratio(ROR)and medicines and healthcare products regulatory agency methods(MHRA)were used to analyse the ADE of tizanidine using FAERS registration data from the first quarter of 2004 to the second quarter of 2022.After valid signals were obtained,the MedDRA was used for translation and system organ classification.Results A total of 7 135 reports of tizanidine ADE were obtained,including 1 732 patients,1 304 ADE types were involved.According to the results of 2 ADE signal mining methods,at the preferred term(PT)level,177 signals were detected.There were 32 PT signals not included in the drug instructions,including potassium wasting nephropathy,cardio-respiratory arrest,and foetal growth restriction etc.In 1 732 patients,the number of ADE cases of female was 2.37 times that in male(1 057 vs.446),and the age group between 40 and 64 accounted for a large proportion(36.03%).The highest proportion(32.79%)reported by consumers.The system organ class involved mainly included various neurological diseases and psychosis.The median time to onset of tizanidine-related ADEs was 75 d(interquartile range:28-223 d),but it was necessary to be vigilant that ADE may still occur 1 year after starting the drug(13.38%).Conclusion This study aims to suggest that clinical application of tizanidin-related ADE should be paid full attention to the occurrence of ADE such as potassium-wasting nephropathy and suicidally completed,as well as key populations such as women and patients of 40-64 years old.

7.
Herald of Medicine ; (12): 639-647, 2024.
Article in Chinese | WPRIM | ID: wpr-1023762

ABSTRACT

Objective To conduct signal mining of adverse events(AEs)of allopurinol and febuxostat based on FAE-RS database,and to explore their potential drug risks and promote rational and safe clinical drug use.Methods The adverse event report data of febuxostat and allopurinol in 22 quarters from the first quarter of 2017 to the second quarter of 2022 were ex-tracted from FAERS database,and the signal mining of febuxostat and allopurinol adverse events(AE)was carried out using ROR method and PRR method.Results There were 5 060 AE reports for allopurinol,concentrated in patients aged≥60 years,in-volving 25 items of system organ classification(SOC),mainly in skin and subcutaneous tissue diseases(40.01%).It was found that 12 SOC categories were not mentioned in the instructions.For febuxostat,there were 905 AE reports,involving 17 SOC items,mainly in cardiac organ diseases(40.17%),and 2 items were not involved in the instructions.Allopurinol and febuxostat were as-sociated with infection and infectious diseases(5.51%,0.49%)and hepatobiliary diseases(5.35%,0.87%),However,these as-sociations were included in the instructions of allopurinol.Allopurinol was associated with the reproductive system and breast dis-eases(0.55%),pregnancy,puerperium and perinatal conditions(0.03%),but febuxostat was not found to be involved in the a-bove SOC.Conclusion The inclusion of adverse reactions in the instructions for allopurinol is relatively inadequate compared to buprostat,and the newly discovered involvement of systemic organs and AE can provide a reference for improving allopurinol in-structions.This study found that allopurinol and febuxostat allopurinol and febuxostat involved system differences,which can pro-vide reference for clinical individualized treatment.

8.
China Pharmacy ; (12): 1374-1378, 2023.
Article in Chinese | WPRIM | ID: wpr-974688

ABSTRACT

OBJECTIVE To provide reference for rational clinical use of mepolizumab. METHODS The reporting odds ratio method and Bayesian confidence propagation neural network method were used to conduct signal mining and analysis of adverse drug event (ADE) reports related to mepolizumab in the United States Food and Drug Administration Adverse Event Reporting System from the first quarter of 2016 to the third quarter of 2022. RESULTS A total of 57 501 ADE reports were extracted with mepolizumab as the primary suspect drug, involving 16 358 patients. Among these reports, the proportion of males (23.51%) was lower than females (50.48%). The reporting countries were primarily the United States (51.91%) and Canada (29.94%). Consumers (71.18%) constituted the main reporting population. A total of 172 ADE-positive signals were identified, mainly involving 13 system organ classes such as the respiratory, thoracic and mediastinal disorders (41.63%), as well as infectious and parasitic diseases (14.16%). There were 60 high-risk signals, including 15 that were explicitly mentioned or related to adverse reactions in the drug instructions of mepolizumab and 45 signals (such as asthmatic crisis, sputum discoloured, purulent sputum, sleep disorder due to a general medical condition) were newly identified high-risk signals. Among them, 11 high-risk signals exhibited gender or age differences. CONCLUSIONS When clinically using mepolizumab, in addition to the adverse reactions mentioned in the drug instruction, special attention should also be given to changes in the nature of sputum, painful respiration, and sleep disorders.

9.
China Pharmacy ; (12): 1622-1626, 2023.
Article in Chinese | WPRIM | ID: wpr-977853

ABSTRACT

OBJECTIVE To provide reference for clinically safe application of avapritinib. METHODS The adverse drug event (ADE) reports of avapritinib from January 9th,2020,to September 30th,2022 were collected from FDA Adverse Event Reporting System (FAERS) database. For data mining and analysis,reporting odds ratio (ROR) method and proportional reporting ratio (PRR) method in the proportional imbalance method were utilized. RESULTS A total of 10 895 ADE reports with avapritinib as the main suspect drug were gathered,and 201 ADE signals involving 19 systematic organ classifications were found after eliminating invalid signals. The instruction of the drugs did not mention any of the ADE,including tinnitus,dementia,chilly limbs, the reduction of blood iron,the reduction of blood sugar,fever,the reduction of vitamin D and vitamin B12,as well as all ADE in the 2 SOCs of musculoskeletal and connective tissue illnesses,diseases of the reproductive system,and diseases of the breast. The majority of the ADE reports 670 cases with complete drug information were for the nervous system (230 cases,accounting for 34.33%) and ocular organ (277 cases,accounting for 41.34%). Compared with other systems,daily dose and treatment course showed significant effects on ADE of neurological system and ocular organ (P<0.05),and the patient’s age had a significant impact on the ADE of the nervous system (P<0.05). CONCLUSIONS A greater incidence of ADE after using avapritinib is present in patients older than 65 with a daily dose of 300 mg/d and a treatment period lasting between 31 and 90 days; patients receiving a daily dose of 300 mg/d and a treatment regimen lasting 31 to 90 days are more likely to experience ADE of the ocular organ. Attention should be given to the aberrant symptoms of the patient’s eyes and nervous system throughout clinical use of avapritinib,and prompt intervention should be given.

10.
China Pharmacy ; (12): 2625-2630, 2023.
Article in Chinese | WPRIM | ID: wpr-997797

ABSTRACT

OBJECTIVE To provide a reference for safe drug use in clinic. METHODS ADE reports related to nilotinib from the first quarter of 2007 to the fourth quarter of 2022 were collected from the US FDA adverse event reporting system database. The reporting odds ratio (ROR) and proportional reporting ratio (PRR) of disproportionality measures were used to mine potential ADE signals,which were compared with drug instruction and related case report, and were screened and analyzed according to the designated medical events (DME) list formulated by the European Medicines Agency. RESULTS Totally 23 332 cases of ADE with nilotinib as the primary suspected drug were reported. A total of 359 positive signals were obtained,involving 24 system organ classes (SOC),mainly concentrated in various examinations,heart organ diseases,vascular and lymphatic diseases,all kinds of nervous system diseases,etc. Among them,ADEs such as vertebral artery stenosis,coronary artery stenosis,arterial disease,liver infection and the second primary malignant tumor were not mentioned in the instructions. Seven DMEs were detected,of which bone marrow failure,pulmonary hypertension and deafness were not mentioned in the drug instruction. CONCLUSIONS The common ADE signals of nilotinib excavated in this study are consistent with the instructions. In clinical use,special attention should be paid to DME not mentioned in the instructions such as bone marrow failure,pulmonary hypertension and deafness; cardiac function, blood glucose and blood lipid indexes should be monitored closely.

11.
China Pharmacy ; (12): 2770-2774, 2023.
Article in Chinese | WPRIM | ID: wpr-998564

ABSTRACT

OBJECTIVE To explore the risk signal of ixazomib and provide a reference for clinically rational drug use. METHODS The Open Vigil 2.1 online tool was used to extract the data of adverse drug events (ADE) reported by the database of FDA adverse event reporting system (FAERS) from the launch of ixazomib in America (November 20th, 2015) to the latest update of the Open Vigil website (March 31st, 2023). The data were mined by using the proportional reporting ratio (PRR) and Bayesian confidence propagation neural network (BCPNN) of the proportional imbalance method. The signals were coded by system organ class (SOC) and preferred term (PT) according to MedDRA v25.1. RESULTS A total of 13 841 ADE reports with ixazomib as the “primary subject” were extracted, involving slightly more male patients (49.53%), and most of them were 65 years old and above (72.48%); the reports came from 57 countries/regions, mainly America (52.90%). A total of 186 positive signals were excavated, with 51 high-intensity, 99 medium-intensity, and 36 low-intensity signals, involving 19 SOCs. The top 50 PT in frequency and signal intensity of PRR included neuropathy peripheral (414 cases, high-intensity signal), platelet count decreased (379 cases, high-intensity signal), thrombocytopenia (360 cases, high-intensity signal), cytopenia (75 cases, high-intensity signal) and neurological symptoms (41 cases, high-intensity signal). SOC involved included nervous system disorders, investigations, and blood and lymphatic system disorders. ADE occurred most frequently in gastrointestinal diseases (2 588 cases), including diarrhea (1 077 cases, high-intensity signal), nausea (737 cases, medium-intensity signal), vomiting (459 cases, medium-intensity signal), constipation (275 cases, medium-intensity signal), and so on. The positive signals of infections and infestations contained the largest number of PTs, and most of them were not recorded in the drug instruction, including 12 high-intensity signals (1 030 cases) and 30 medium-intensity signals (627 cases), which were mainly distributed in lung infection, upper respiratory infection, gastrointestinal infection, sepsis, herpes zoster and so on. The signals of cardiac amyloidosis (7 cases, high-intensity signal) and acute coronary syndrome (14 cases, high-intensity signal) of cardiac disorders and renal dysfunction (91 cases, medium-intensity signal) of renal and urinary disorders were all strong and had not been recorded in the drug instruction. CONCLUSIONS In addition to routine attention to the common ADE of ixazomib in gastrointestinal diseases,nervous system disorders and blood and lymphatic system disorders, clinical attention should also be paid to various infections that may occur during the treatment of patients, and the occurrence of cardiovascular toxicity and renal dysfunction should be monitored.

12.
China Pharmacy ; (12): 2391-2395, 2023.
Article in Chinese | WPRIM | ID: wpr-996397

ABSTRACT

OBJECTIVE To provide a reference for the safe use of thrombopoietin receptor agonists romiplostim and eltrombopag in clinic. METHODS FDA adverse event reporting system (FAERS) in the United States was adopted to collect adverse drug event (ADE) reports of romiplostim and eltrombopag from their launch in the United States to September 30, 2022; the ADE signals of the two drugs were analyzed using the reporting odds ratio (ROR) method and the comprehensive standard method of the UK Medicines and Healthcare Products Regulatory Agency. RESULTS A total of 14 021 and 4 431 ADE reports were collected about romiplostim and eltrombopag, respectively, with a gender composition of more females than males. After signal screening, 563 ADE signals were obtained about romiplostim, involving 25 system organ classes (SOC); eltrombopag had 433 ADE signals, involving 26 SOC. The most frequently reported ADE for both drugs was platelet count decreased (2 060, 1 585 cases), which was mentioned in their drug instructions. In terms of signal intensity, romiplostim exhibited the highest signal for abnormal thrombopoietin levels (ROR of 2 268.85), while eltrombopag had the highest signal for positive dengue virus test (ROR of 954.50), with neither of these signals mentioned in their respective drug instructions. CONCLUSIONS The ADE of romiplostim and eltrombopag mainly affects the blood and lymphatic system, and there are many new suspicious high-risk signals.

13.
China Pharmacy ; (12): 2513-2518, 2023.
Article in Chinese | WPRIM | ID: wpr-997011

ABSTRACT

OBJECTIVE To provide references for the safe use of lorlatinib in clinical practice. METHODS The reporting odds ratio (ROR) method, Medicines and Healthcare Products Regulatory Agency comprehensive standard method (referred to as “MHRA method”) and the Bayesian confidence propagation neural network (BCPNN) method were used to detect adverse drug events (ADEs) signals of lorlatinib in the FDA Adverse Event Reporting System from the first quarter of 2019 to the fourth quarter of 2022. RESULTS & CONCLUSIONS Totally 114 overlapping ADEs signals of lorlatinib were detected by the three methods, among which there were 73 new suspicious ADEs signals which were not covered in the instruction of lorlatinib. When using loratinib in clinical practice, special attention should be paid to ADEs with a high number of cases and signals, such as various neurological diseases, psychiatric diseases, respiratory system, thoracic and mediastinal diseases; clinical manifestations included cerebral edema, cerebral infarction, pulmonary hypertension, mutism, decreased sexual desire, pleural effusion. The signals of mobile thrombophlebitis, radiation necrosis, mutism, vesicoureteral reflux not mentioned in the instructions were all strong in BCPNN detection with high specificity, to which we should pay attention in clinical application.

14.
China Pharmacy ; (12): 1865-1869, 2022.
Article in Chinese | WPRIM | ID: wpr-936493

ABSTRACT

OBJECTIVE To exc avate the adverse drug event (ADE)signals of semaglutide and provide reference for its clinical rational use. METHODS The proportional unbalance method was used to mine the signals of all semaglutide ADE reports from FDA Adverse Event Reporting System (FAERS)up to September 2021. The basic situations of the reported cases were analyzed. The corresponding system organ classification (SOC)was mapped and compared with the adverse drug reactions recorded in the drug instructions. Preferred terms (PT)of patients with different indications were analyzed. RESULTS A total of 6 661 semaglutide ADE reports were extracted and 194 valid signals were mined. Among 6 661 cases of ADE ,the proportion of men (43.40%)was lower than women (52.65%);the age was mainly distributed in >40-65 years old (29.00%)and >65 years old (22.61%);the reporting country was mainly the United States (83.88%);the report year was mainly concentrated in 2021 (40.88%),with an increasing trend year by year ;the main outcome was hospitalization or prolonged hospitalization in serious ADE reports (17.78%). Semaglutide ADE signal was mapped to the main SOC ,mainly including gastrointestinal diseases ,various injuries,poisoning and operation complications ,metabolic and nutritional diseases ,various examinations. The screening criteria were based on the report odds ratio >10 or ADE reported cases >50,and 48 new potential adverse drug reactions were added to the drug description. Among the indications with the top two reported cases (type 2 diabetes and obesity ,overweight,weight control),the frequency of gastrointestinal system related ADE reports represented by nausea ,vomiting and diarrhea was higher , which was similar to the drug instructions. CONCLUSIONS This study supplemented 48 new potential adverse drug reactions based on the drug instructions of semaglutide. At present ,it can be considered that semaglutide is safe.

15.
China Pharmacy ; (12): 1485-1491, 2022.
Article in Chinese | WPRIM | ID: wpr-927197

ABSTRACT

OBJECTIVE To mine and analyze the risk signal of glucagon- like peptide -1 receptor agonists (GLP-1RA)related adverse drug reaction (ADR). METHODS ADR data related to GLP- 1RA from April 1,2005 to October 16,2021 in the openFDA database were collected ,and the Bayesian confidence propagation neoral network (BCPNN)method was used for data mining. ADR were classified and described by using systematic organ classification (SOC)of drug ADR terminology set in 24.0 edition of MedDRA. RESULTS & CONCLUSIONS A total of 175 719 ADR reports related to GLP- 1RA were retrieved ,with 140 ADR positive signals ,involving five drugs such as exenatide (77 027 cases of ADR and 31 ADR positive signals ),dulaglutide (45 329 cases of ADR and 26 ADR positive signals ),liraglutide (42 748 cases of ADR and 32 ADR positive signals ), semaglutide(8 844 cases of ADR and 27 ADR positive signals )and lixisenatide (1 771 cases of ADR and 24 ADR positive signals). According to SOC classification ,GLP-1RA-induced ADR involved gastrointestinal system ,hepatobiliary system ,nervous system,urinary and renal system ,endocrine system ,immune system and administration site. In the gastrointestinal system ,the risk of (acute)pancreatitis was higher ,and the order of risk was liraglutide >exenatide>semaglutide>dulaglutide>lixisenatide; ADR signal of hepatobiliary system was stronger for cholelithiasis ,and the order of risk was liraglutide >semaglutide>exenatide> lixisenatide>dulaglutide. In the nervous system ,the risk of taste disorder was higher ;compared with dulaglutide and lixisenatide , liraglutide,exenatide and semaglutide were more likely to cause headache and dizziness. In urinary and renal system , compared with exena tide,dulaglutide and lixisenatide ,liraglutide and semaglutide were more likely to cause acute renal injury. In the endocrine system ,the risk of hypoglycemia was higher ,and the order of risk was exenatide >liraglutide>lixisenatide> semaglutide>dulaglutide. In the immune system ,lixisenatide was more likely to develop urticaria than other drugs ,dulaglutide and liraglutide did not caused ADR signal. Among the administration sites ,the risk of ADR caused by exenatide and dulaglutide was higher,while the risk of related ADR caused by semaglutide was lower. When using GLP- 1RA clinically ,we should closely monitor the renal function and blood glucose of patients ,and pay attention to patients with sudden upper abdominal pain ;in case of relevant ADR ,timely intervention measures should be taken to ensure the safety and effectiveness of medication.

16.
China Pharmacy ; (12): 2129-2132, 2022.
Article in Chinese | WPRIM | ID: wpr-941455

ABSTRACT

OBJECTIVE To mine the risk sig nals o f iodine contrast media from spontaneous reporting system. METHODS Reporting odds ratio ,proportional reporting ratio ,Medicines and Healthcare Products Regulatory Agency and Bayesian confidence propagation neural network were used to mine risk signals of 5 iodine contrast media (iopamidol,iohexol,iopromide,ioversol, iodixanol). RESULTS 1 164(2 446 case times )adverse drug reaction of iodine contrast media were included ,a total of 14 risk signals involving systems/organs such as respiratory system (3,2,4,3,2 for the above 5 iodine contrast media )and immune system and 32 specific adverse drug reaction signals including anaphylactic shock ,rash and flushing (11,7,7,3,4 for the above 5 iodine contrast media )were found in 5 iodine contrast media. CONCLUSIONS The risk signals of 5 iodine contrast media verify that there is a certain correlation between these drugs and above adverse drug reactions. It is suggested that before using iodine contrast media in clinic ,it is necessary to pay attention to whether the patient has a history of tumor and combined medication ,evaluate the patient’s renal function ,and give preventive measures such as hydration in advance. When using iodine contrast media ,it is necessary to pay attention to the temperature ,dose and injection rate. And medical staff need to follow up the patient ’s situation in time after using iodine contrast media to avoiding the impact of delayed adverse reactions.

17.
China Pharmacy ; (12): 352-357, 2022.
Article in Chinese | WPRIM | ID: wpr-913095

ABSTRACT

OBJECTIVE To mine the signals of adverse dr ug events (ADE)for tolvaptan based on FAERS database ,and to provide reference for safe use of drugs in clinic. METHODS The data of tolvaptan-induced ADE were collected from FAERS database during the first quarter of 2004 to the third quarter of 2020;the reporting odds ratio (ROR)method and the proportional reporting ratio (PRR)method of disproportional method were used for data mining. RESULTS A total of 4 744 ADE reports of the target drug tolvaptan were extracted ,involving 1 279 ADEs. The reporting countries were mainly the United States and Japan ,etc. A total of 199 ADE signals were obtained ,involving 21 system organ classes (SOCs),which mainly focused on various examinations(n=56),hepatobiliary disorders (n=17),renal and urinary disorders (n=14),etc. Among them ,80 signals were not mentioned in existing instructions for tolvaptan in China ,such as decreased glomerular filtration rate ,positional vertigo , rupture of renal cyst ,renal cyst infection ,pulmonary malignant tumor. CONCLUSIONS Before using tolvaptan ,drug evaluation should be performed well ,especially the patients with basic diseases such as heart failure ,liver insufficiency and renal insufficiency. During treatment ,the indexes of liver function and renal function should be closely monitored ;timely intervention measures should be taken to avoid related injury and disease deterioration caused by ADE when ADE or disease progression occurs.

18.
Article in Chinese | WPRIM | ID: wpr-986647

ABSTRACT

Objective To explore the potential adverse reactions of acalabrutinib by mining and analyzing the pharmacovigilance signal of acalabrutinib, to provide a reference for clinically safe and rational drug use. Methods Data related to acalabrutinib in the FAERS database were searched, and pharmacovigilance signals were obtained using the disproportionality measurement. Results A total of 3, 155 reports of adverse events with acalabrutinib as the primary suspected drug were extracted, and 73 warning signals were detected involving 15 system organ classifications, 36 of which were not included in the drug instructions of acalabrutinib. The strong signals of acalabrutinib were mainly concentrated in various inflammatory and bleeding, anemia, contusion, atrial fibrillation, and so on. The largest number of system organ classification signals were focused on the blood and lymphatic system disorders, investigations, infections, and so on. In addition, the drug may cause tachycardia, brittle nails, and other warning signs. Through further analysis of gender-related adverse events, there were a total of 49 high-risk signals with gender differences found. Herein, male patients should pay attention to adverse reactions in bleeding, heart, urinary system, hypertension, and so on; meanwhile, female patients should be alert to adverse reactions in liver function, skin inflammation, and so on. Conclusion A total of 36 drug warning signs that are not mentioned in the instructions for acalabrutinib are mined using FAERS, and blood, infection, and cardiac toxicity require special attention. Thus, these signals should be detected promptly for effective prevention in clinical medication to reduce the risk of medication use for patients.

19.
China Pharmacy ; (12): 3024-3030, 2021.
Article in Chinese | WPRIM | ID: wpr-906785

ABSTRACT

OBJECTIVE:To prov ide referen ce for clinical safe and rational use of belimumab by mining the risk signals of adverse drug event (ADE). METHODS :ADE reports related to belimumab were collected from FDA adverse event reporting system(FAERS)from the first quarter of 2015 to the first quarter of 2021. The reporting odds ratio (ROR)method and the Medicines and Healthcare Products Regulatory Agency (MHRA)method were adopted to mine the ADE risk signals related to belimumab,setting the threshold as the number of reports >3 and the lower limit of 95% CI >1(ROR method )and the proportional reporting ratio (PRR)>2,and χ2 >4(MHRA method ). ADEs were counted and classified by using the preferred system organ class (SOC)and preferred term (PT)of Medical Dictionary for Regulatory Activities (MedDRA). RESULTS & CONCLUSIONS:A total of 3 529 ADE reports with belimumab as the primary suspicious drug were screened ,in which female patients(90.31%)were much more than male patients (6.15%);age distribution was concentrated in 18-59 years old (41.80%). There were 1 234 cases(34.97%)of severe ADE reports ,mainly involving hospital or prolonged hospital stay. Most of the reporters were consumers or other non-medical professionals (81.84%). North America reported the most (70.39%)and the main reporting country was the United States (2 029 reports). A total of 180 PTs were mined from 3 529 reports,in addition to PTs associated with primary disease (systemic lupus erythematosus ,pain,arthralgia,pyrexia,weight decreased ,swelling,oropharyngeal pain , etc.),PTs related to medication error (product dose omission ,inappropriate schedule of product administration ,underdose, product availability issue ,etc.)and PTs related to infection (influenza,urinary tract infection ,infection,sinusitis,etc.)were reported in a large number of cases. Twenty-six SOCs were involved ,the top 10 SOC in ADE reports were all kinds of injuries , poisoning and surgical complications (2 225 reports),infections and infectious diseases (1 247 reports),general disorders and administration site conditions (1 196 reports),musculoskeletal and connective tissue disorders (1 195 reports),surgical and medical procedures(515 reports),etc. PTs in SOC in the first place (all kinds of injuries ,poisoning and surgical complications )of ADE reports were all related to medication error ;herpes zoster ,kidney infection and cellulitis in SOC in the second place (infections and infectious diseases )of ADE reports were not included in the drug instruction of belimumab ;most PTs in SOCs such as various nervous system diseases ,immune system diseases ,mental diseases ,benign,malignant and unknown tumors (including cystic and polypoid)which were taken attention in clinic were not included in the drug instruction of belimumab. It is suggested to avoid medication errors as far as possible in clinical use of belimumab ,and to guard against adverse reactions such as herpes zoster , kidney infection ,cellulitis and various nervous system diseases ,immune system diseases and mental diseases. In addition ,the patients with malignant tumor or related history should use belizumab carefully.

20.
China Pharmacy ; (12): 236-240, 2021.
Article in Chinese | WPRIM | ID: wpr-862650

ABSTRACT

OBJECTIVE:To initially evaluate the safety of ceritinib after it is marketed ,and to provide reference for the rational use of drug. METHODS The report odd ratio method and proportional reporting ratio method were used to mine the signals of ceritinib-related adverse events from FDA adverse event reporting system (FAERS)during the second quarter of 2014 to the third quarter of 2019. The patients ’gender,age,body weight ,daily dose and course of treatment were collected. SPSS 26.0 software was used to test the number of ADR cases of this system group and other system groups by chi square test. RESULTS :A total of 10 318 ADR reports with ceritinib as the first suspicious drug were collected , and 236 ADR signals of seretinib were excavated. After excluding the ineffective treatment ,187 ADR signals were obtained ,involving 16 systems. Inaddition to those mentioned in the drug instructions ,the signals also included various nervous disease ,blood and lymph system disease ,infections and infectious disease ,etc.,such as hand-foot-genital syndrome ,mutation of anaplatic lymphoma kinase gene. Among them ,the ADR reports of gastrointestinal diseases were the most (576 cases). Compared with ADR of other systems ,gender,age,body weight,daily dose and treatment course had significant effects on ADR of gastrointestinal diseases (P<0.05). Most of the patient with gastrointestinal ADR after using ceritinih were female (59.9%),45 years old and above (70.3%),body weight ≤65 kg (68.1%),daily dose 451-750 mg/d(50.2%),and medication duration less than 3 months(75.7%). CONCLUSIONS :The risk of gastrointestinal ADR in female patients over 45 years old and with body weight less than 65 kg after using seretinib is relatively high. This kind of ADRs are also related to daily dose ,and most of which occur within 3 months. Therefore ,great importance should be attached to drug monitoring during clinical use.

SELECTION OF CITATIONS
SEARCH DETAIL